Lipase variants for pharmaceutical use

A lipase and drug technology, applied in the field of determination, can solve problems such as undescribed drug use

Inactive Publication Date: 2015-12-02
NOVOZYMES AS
View PDF45 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] WO92 / 05249, WO92 / 19726, WO94 / 25577, WO95 / 09909, WO95 / 22615, WO97 / 04079, WO97 / 07202, WO99 / 42566, WO00 / 32758, WO00 / 60063, WO01 / 83559, WO01 / 83559, WO2002 / 055679, WO2002 / 062973, WO2002 / 062973, WO2004 / 099400 and WO2004 / 111216 describe variants of SEQ ID NO: 2, but do not describe their pharmaceutical use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lipase variants for pharmaceutical use
  • Lipase variants for pharmaceutical use
  • Lipase variants for pharmaceutical use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[1181] (a) purify the lipase used in step ii); (b) dilute the lipase locally, usually 25 to 200 times in a diluent (for example 0.01% Triton-X100, 10 mM NaCl), for example to about 8 μg / mL; (c) using an extinction coefficient of 1.24A 280 / mg The concentration of the purified lipase sample was determined from the absorbance at 280nm; (d) an OD of about 0.100-0.475 in the linear range; and / or (e) the bile salt was Sigma B-8756, made 20 mM in distilled water.

[1182]In a further particular embodiment (f) of step vi), the proportion of the activity in the presence of bile salts at pH 5.0 is expressed as a percentage by calculating step v corrected for time and dilution of the "bile salt" activity ) divided by the mean of all linear data corrected for time and dilution of "no bile salt" activity.

[1183] (A) In a first specific embodiment, the lipase of the invention is selected from lipases having the following substitutions, preferably a set of substitutions, as compared to t...

Embodiment 1

[2437] Example 1: Enzyme Assay

[2438]Methods for the determination of lipase, protease and amylase activity in porcine pancreatin have been published by FIP (Fédération Internationale Pharmaceutique) as well as European Pharmacopoeia and United States Pharmacopoeia. Such assays are described eg in: Fédération Internationale Pharmaceutique, Scientific Section: International Commission on Standardization of Enzymes for Pharmaceutical Use. a) "Pharmaceutical Enzymes," Editors: R. Ruyssen and A. Lauwers, E. Story Scientia, Ghent, Belgium (1978), b) European Pharmacopoeia. See also Deemester et al. in Lauwers A, Scharpé S (eds): Pharmaceutical Enzymes, New York, Marcel Dekker, 1997, pp. 343-385. Suitable enzyme standards can be obtained from the International Commission on Pharmaceutical Enzymes, Centre for Standards, Harelbekestraat 72, B-9000 Ghent.

[2439] The lipase FIP assay and other suitable assays for lipases, proteases and amylases are described below.

[2440] Lip...

Embodiment 2

[2469] Example 2: Lipase variants with improved phospholipase activity

[2470]DNA encoding the lipase variants shown in Table 1 below was transformed into Aspergillus oryzae strain ToC1512 (described in WO2005 / 070962) using the method described in Example 22 of U.S. Patent No. 5,869,438 except that PyrG selection (described in WO2004 / 069872) instead of AMDS selection. Spores of the Aspergillus oryzae host were obtained from an agar slant and used to inoculate 10ml of YPM (10g yeast extract, Difco + 20g peptone, Difco, add water to 1 L, autoclave it; add sterile-filtered maltose to 2% (w / w )). The inoculated tubes were incubated in a New Brunswick Scientific Innova 2300 shaker at 180 rpm at 30°C for 3 days. The supernatant was harvested by filtration of the culture through Mira-Cloth (Calbiochem) followed by sterile filtration through a 0.45um (micrometer) filter. The lipase variants were purified as generally described in Example 23 of US Patent No. 5,869,438.

[2471] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to view more

Abstract

The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, with at least substitutions N33Q, T231R, N233R and D254S optionally in combination with a protease and / or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and / or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, are stable against protease-degradation, and / or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.

Description

[0001] The application of the present invention is based on the application date of December 12, 2007, the application number is "200780051638.6" (the international application number is PCT / US2007 / 087168), and the invention patent application named "lipase variant for pharmaceutical use" divisional application. [0002] References to Sequence Listings [0003] This application also has a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference. technical field [0004] The present invention relates to a lipase (a) having at least 50% identity to the sequence of amino acids 1-269 of SEQ ID NO: 2; (b) having lipase activity; Compared to the sequence of amino acids 1-269 of SEQ ID NO: 2, comprising the substitutions N33Q, T231R and N233R, and at least one additional substitution selected from the group consisting of: E1*, D, N; Q4H, P, R; D5E; N8L, Q ;Q9H;F10L;N11C,D,H,L,P,Q,R,S;G23E;N26A,H,I;D27I,N,Q,R,S,V;P29T;A30T,V;T37K,M ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N9/20A61K38/46A61P1/00A61P1/18A61P3/10
CPCA61K38/465A61K38/47A61K38/48C12N9/20C12Y301/01003A61K38/00A61P1/00A61P1/14A61P1/18A61P3/00A61P3/10A61P3/08A61P43/00A61K38/46A61K38/54
Inventor 阿伦·斯文德森迈克尔·斯克乔伊特戴比·亚弗拉斯·L·H·克里斯滕森西格恩·E·拉森尼娜·伦丁迈克尔·拉姆萨彼得·C·格雷戈里
Owner NOVOZYMES AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap